SANGUI BIOTECH INTERNATIONAL INC
sanguibiotech.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed May 12, 2023. Its latest SEC filing is a REVOKED from Jul 3, 2025.
10-Q for Q3 FY2023, filed May 12, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops and markets wound sprays and dressings for end users, and develops artificial oxygen carriers for medical use.
10-K for FY2022, filed Sep 28, 2022Our mission is the development of novel and proprietary pharmaceutical, medical and cosmetic products. We develop our products through our…View ↗
Our focus has been the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic…View ↗
In addition, we have developed external applications of oxygen transporters, in the medical and cosmetic fields, in the form of sprays for…View ↗
We also market a wound dressing that shows outstanding wound healing support properties, which we call Chitoskin. Sangui GmbH holds…View ↗
Our current key business focuses are: (a) selling our existing wound management products through distribution partners, or by way of direct…View ↗
How Did They Make Money?
Sangui earns a percentage-based licensing fee on wound-spray sales; royalties are triggered when its licensee makes the sales that qualify.
10-K for FY2022, filed Sep 28, 2022The basic terms of the licensing contract agreement are that Sangui GmbH is awarded a fixed licensing fee as a percentage of the external…View ↗
During the period and in previous year the Company derives revenue only from licensing fees on sales of its wound spray product from one…View ↗
The Company’s licenses provide a right to use and create performance obligations satisfied at a point in time. The Company recognizes…View ↗
$69.2K
-
10-K for FY2022, filed Sep 29, 2022
$69.2K ↗
Who Were Their Customers?
Mölnlycke Health Care is the licensee for Granulox and generated all company revenue; Sangui says it sells wound-management products through distribution partners or directly to end users.
10-K for FY2022, filed Sep 28, 2022
Did Revenues Turn Into Profits?
No. It lost $59.3K in FY2022.
10-K for FY2022, filed Sep 29, 2022
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2023, filed May 13, 2023
−$38.2KView ↗
- ▲ +157% (Loss)
- vs −$14.9K in Q3 FY2022
-
Nov 3, 2022
OTC Markets began OTCQB delisting proceedings
The stock moved to the Pink Market and remained available to trade there.
Sources
8-K, filed Nov 3, 2022
On October 31, 2022, Sangui BioTech International, Inc. (the “Company” or “Sangui”) was notified by the OTC Markets Group (the “OTC”) that…View ↗
Distribution partner
The older report names SastoMed as Granulox’s distributor; the latest names Mölnlycke, after the license transferred in Sastomed’s merger.
10-K for FY2019, filed Oct 8, 2019 10-K for FY2022, filed Sep 28, 2022A wound dressing spray we developed that shows outstanding properties in the support of wound healing is being distributed by SastoMed…View ↗
Who Did They Compete With?
Competes with Johnson & Johnson, Bristol-Myers Squibb, Coloplast, and BSNmedical
10-K for FY2022, filed Sep 28, 2022The market for our products and technologies is highly competitive, and we expect competition to increase. In the fields of anti-aging and…View ↗
Loading...
